Axsome Therapeutics (AXSM) Competitors

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Do insiders & institutionals hold more shares of AXSM or JAZZ?

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk & volatility, AXSM or JAZZ?

Axsome Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

Is AXSM or JAZZ more profitable?

Jazz Pharmaceuticals has a net margin of 11.86% compared to Axsome Therapeutics' net margin of -64.39%. Jazz Pharmaceuticals' return on equity of 26.62% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-64.39%	-272.80%	-36.69%
Jazz Pharmaceuticals	11.86%	26.62%	9.14%

Does the media favor AXSM or JAZZ?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 17 mentions for Axsome Therapeutics and 9 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.78 beat Axsome Therapeutics' score of -0.04 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer AXSM or JAZZ?

Axsome Therapeutics currently has a consensus price target of $172.33, indicating a potential upside of 60.31%. Jazz Pharmaceuticals has a consensus price target of $184.00, indicating a potential upside of 71.00%. Given Jazz Pharmaceuticals' higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	3.06
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92

Which has stronger earnings and valuation, AXSM or JAZZ?

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$385.69M	13.72	-$287.22M	-$5.77	-18.63
Jazz Pharmaceuticals	$4.06B	1.60	$560.12M	$7.50	14.35

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.